The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MBNKF, TEVA and OMCL

NEW YORK, NY / ACCESSWIRE / July 23, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Metro Bank PLC MBNKF
Class Period: March 6, 2018 to May 1, 2019
Lead Plaintiff Deadline: July 29, 2019

The lawsuit alleges that Metro Bank PLC made materially false and/or misleading statements and/or failed to disclose that: (1) Metro Bank misclassified the risk terms of many of its loans; (2) accordingly, Metro Bank failed to maintain sufficient capital; (3) this conduct would lead to investigations by the PRA and FCA; (4) this conduct would also lead to the reduction of deposits at Metro Bank from larger commercial and partnership clients; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in MBNKF: http://www.kleinstocklaw.com/pslra-1/metro-bank-plc-loss-submission-form?id=2553&from=1

Teva Pharmaceutical Industries Ltd. TEVA
Class Period: on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares ("ADS") between August 4, 2017 and May 10, 2019
Lead Plaintiff Deadline: August 23, 2019

The lawsuit alleges Teva Pharmaceutical Industries Ltd. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Learn about your recoverable losses in TEVA: http://www.kleinstocklaw.com/pslra-1/teva-pharmaceutical-industries-ltd-loss-submission-form?id=2553&from=1

Omnicell, Inc. OMCL
Class Period: October 25, 2018 to July 11, 2019
Lead Plaintiff Deadline: September 16, 2019

During the class period, Omnicell, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in OMCL: http://www.kleinstocklaw.com/pslra-1/omnicell-inc-loss-submission-form?id=2553&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm